financetom
Business
financetom
/
Business
/
Uber Investors Cautious Ahead of Q4 Results Amid Robotaxi Concerns, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber Investors Cautious Ahead of Q4 Results Amid Robotaxi Concerns, Oppenheimer Says
Feb 3, 2025 9:48 AM

12:19 PM EST, 02/03/2025 (MT Newswires) -- Uber Technologies ( UBER ) investors remain cautious ahead of its Q4 results amid Robotaxi concerns, though in-line results, especially around mobility, should drive the stock higher, Oppenheimer said in a note e-mailed Monday.

The ride-hailing giant is scheduled to report Q4 results Wednesday. Oppenheimer expects earnings of $0.45 a share on revenue of about $11.81 billion.

"We believe Robotaxi will be a [total addressable market] expander for Uber ( UBER ) assuming Tesla (TSLA) does not become the only full self-driving company and believe Tesla Robotaxi enthusiasm will fade without meaningful improvement over the next 12-18 months," Oppenheimer analysts, including Jason Helfstein, said in a note to clients.

The brokerage reiterated Uber ( UBER ) as its "best idea heading into Q4 results," but acknowledged the risk around Robotaxi update, the analysts said.

Oppenheimer has an outperform rating on the stock, with an $85 price target

Uber ( UBER ) shares were up more than 2% in recent trading.

Price: 68.52, Change: +1.67, Percent Change: +2.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dentsply Sirona Misses Q2 Targets - Plans Restructuring Plan Amid Weak Demand
Dentsply Sirona Misses Q2 Targets - Plans Restructuring Plan Amid Weak Demand
Jul 31, 2024
DENTSPLY SIRONA Inc. ( XRAY ) shares are trading higher on Wednesday. The company reported second-quarter adjusted earnings per share of 49 cents, missing the street view of 50 cents, and quarterly sales of $984 million, missing the analyst consensus of $995.66 million. According to William Blair analyst Brandon Vazquez, largest miss came from Connected Technology Solutions (equipment), which was...
Update: CrowdStrike Hit With First Class Action Suit Over Global Outage
Update: CrowdStrike Hit With First Class Action Suit Over Global Outage
Jul 31, 2024
11:45 AM EDT, 07/31/2024 (MT Newswires) -- (Updates to add CrowdStrike's ( CRWD ) response to request for comment in the last two paragraphs.) CrowdStrike Holdings ( CRWD ) was hit with a federal securities class action complaint stemming from a late-July update to its cybersecurity software that caused a global outage across several industries. According to the complaint, filed...
Mastercard Second-Quarter Results Top Views; Third Quarter 'Generally Stable' so Far
Mastercard Second-Quarter Results Top Views; Third Quarter 'Generally Stable' so Far
Jul 31, 2024
11:45 AM EDT, 07/31/2024 (MT Newswires) -- Mastercard's ( MA ) results rose more than expected in the second quarter amid healthy consumer spending and demand for value-added services, while the payments firm said it expects double-digit revenue growth in the third quarter. Adjusted earnings per share climbed to $3.59 from $2.89 last year and topped the $3.51 average analyst...
Rhythm Pharmaceuticals Gets European Commission's Expanded Authorization for Obesity Drug
Rhythm Pharmaceuticals Gets European Commission's Expanded Authorization for Obesity Drug
Jul 31, 2024
11:45 AM EDT, 07/31/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Wednesday that it received expanded marketing authorization for Imcivree from the European Commission to include children between 2 and 6 years old with rare neuroendocrine diseases. The expanded authorization for Imcivree, or setmelanotide, now includes children 2 years up to under 6 years old with obesity due...
Copyright 2023-2026 - www.financetom.com All Rights Reserved